94 related articles for article (PubMed ID: 12091065)
1. Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
Raymond E; Campone M; Stupp R; Menten J; Chollet P; Lesimple T; Fety-Deporte R; Lacombe D; Paoletti X; Fumoleau P; ; ;
Eur J Cancer; 2002 Jul; 38(10):1348-50. PubMed ID: 12091065
[TBL] [Abstract][Full Text] [Related]
2. Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
de Jonge MJ; Droz JP; Paz-Ares L; van Oosterom AT; de Wit R; Chollet P; Baron B; Lacombe D; Mettinger K; Fumoleau P;
Invest New Drugs; 2004 Aug; 22(3):329-33. PubMed ID: 15122081
[TBL] [Abstract][Full Text] [Related]
3. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Raymond E; Fabbro M; Boige V; Rixe O; Frenay M; Vassal G; Faivre S; Sicard E; Germa C; Rodier JM; Vernillet L; Armand JP
Ann Oncol; 2003 Apr; 14(4):603-14. PubMed ID: 12649109
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
Baka S; Ranson M; Lorigan P; Danson S; Linton K; Hoogendam I; Mettinger K; Thatcher N
Eur J Cancer; 2005 Jul; 41(11):1547-50. PubMed ID: 16026691
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Brandes AA; Tosoni A; Basso U; Reni M; Valduga F; Monfardini S; Amistà P; Nicolardi L; Sotti G; Ermani M
J Clin Oncol; 2004 Dec; 22(23):4779-86. PubMed ID: 15570079
[TBL] [Abstract][Full Text] [Related]
6. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin.
Rubin E; Wood V; Bharti A; Trites D; Lynch C; Hurwitz S; Bartel S; Levy S; Rosowsky A; Toppmeyer D
Clin Cancer Res; 1995 Mar; 1(3):269-76. PubMed ID: 9815982
[TBL] [Abstract][Full Text] [Related]
7. The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
Gerrits CJ; Schellens JH; Creemers GJ; Wissel P; Planting AS; Pritchard JF; DePee S; de Boer-Dennert M; Harteveld M; Verweij J
Br J Cancer; 1997; 76(7):946-51. PubMed ID: 9328158
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors.
Zamboni WC; Jung LL; Egorin MJ; Potter DM; Friedland DM; Belani CP; Agarwala SS; Wong MM; Fakih M; Trump DL; Jin R; Strychor S; Vozniak M; Troetschel M; Ramanathan RK
Clin Cancer Res; 2004 Aug; 10(15):5058-64. PubMed ID: 15297407
[TBL] [Abstract][Full Text] [Related]
9. Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Schöffski P; Herr A; Vermorken JB; Van den Brande J; Beijnen JH; Rosing H; Volk J; Ganser A; Adank S; Botma HJ; Wanders J
Eur J Cancer; 2002 Apr; 38(6):807-13. PubMed ID: 11937315
[TBL] [Abstract][Full Text] [Related]
10. Pre-irradiation 9-amino [20s] camptothecin (9-AC) in patients with newly diagnosed glioblastoma multiforme.
Farray D; Ahluwalia MS; Snyder J; Barnett GH; Cohen BH; Suh JH; Peereboom DM
Invest New Drugs; 2006 May; 24(3):177-80. PubMed ID: 16086097
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
Creemers GJ; Gerrits CJ; Eckardt JR; Schellens JH; Burris HA; Planting AS; Rodriguez GI; Loos WJ; Hudson I; Broom C; Verweij J; Von Hoff DD
J Clin Oncol; 1997 Mar; 15(3):1087-93. PubMed ID: 9060549
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.
Grossman SA; Carson KA; Phuphanich S; Batchelor T; Peereboom D; Nabors LB; Lesser G; Hausheer F; Supko JG;
Neuro Oncol; 2008 Aug; 10(4):608-16. PubMed ID: 18577560
[TBL] [Abstract][Full Text] [Related]
13. A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors.
Yan Z; Zhu Z; Li K; Chen P; Wang L; Huang C; Xue J; Liu M
Cancer Chemother Pharmacol; 2011 Apr; 67(4):955-61. PubMed ID: 21191594
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Herben VM; van Gijn R; Schellens JH; Schot M; Lieverst J; Hillebrand MJ; Schoemaker NE; Porro MG; Beijnen JH; ten Bokkel Huinink WW
J Clin Oncol; 1999 Jun; 17(6):1906-14. PubMed ID: 10561232
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial of oral gimatecan for recurrent glioblastoma.
Hu J; Wen PY; Abrey LE; Fadul CE; Drappatz J; Salem N; Supko JG; Hochberg F
J Neurooncol; 2013 Feb; 111(3):347-53. PubMed ID: 23232808
[TBL] [Abstract][Full Text] [Related]
16. Lack of efficacy of 9-aminocamptothecin in adults with newly diagnosed glioblastoma multiforme and recurrent high-grade astrocytoma. NABTT CNS Consortium.
Hochberg F; Grossman SA; Mikkelsen T; Glantz M; Fisher JD; Piantadosi S
Neuro Oncol; 2000 Jan; 2(1):29-33. PubMed ID: 11302251
[TBL] [Abstract][Full Text] [Related]
17. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
Punt CJ; de Jonge MJ; Monfardini S; Daugaard G; Fiedler W; Baron B; Lacombe D; Fumoleau P;
Eur J Cancer; 2004 Jun; 40(9):1332-4. PubMed ID: 15177492
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas.
Posey JA; Saif MW; Carlisle R; Goetz A; Rizzo J; Stevenson S; Rudoltz MS; Kwiatek J; Simmons P; Rowinsky EK; Takimoto CH; Tolcher AW
Clin Cancer Res; 2005 Nov; 11(21):7866-71. PubMed ID: 16278410
[TBL] [Abstract][Full Text] [Related]
19. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]